Vishnevskaia E E
Med Radiol (Mosk). 1988 Apr;33(4):44-50.
The paper is concerned with the results of a study of efficacy of combined radiation therapy of 771 cervical cancer patients: 153 of them (the 1st group) received standard intracavitary gamma-therapy, 206 (the 2nd group)--intracavitary gamma-therapy based on the principle of successive insertion of endostats and low activity radionuclide sources, and 412 (the 3rd group)--on the principle of successive insertion of high activity sources. The patients were comparable with respect to the main clinical symptoms and biological tumor features. The frequency of radiation reactions and complications turned out to be higher in the 1st group. In the 1st group the 5-year survival rate for patients with stage I cervical cancer was 76.2 +/- 6.9%, for patients with stage II--65.5 +/- 5.1%, for patients with stage III tumors--39.2 +/- 9.2%. For the 2nd group these indices were 95.7 +/- 2.9; 75.1 +/- 4 and 58.5 +/- 7.7%, respectively, for the 3rd group--96.4 +/- 1.6; 85.9 +/- 2.8; 59.7 +/- 9.3%, respectively. The author has proved the advantages of the method of combined radiation therapy of cervical cancer using intracavitary gamma-therapy based on the principle of two-staged successive insertion of endostats and high activity sources.
本文涉及对771例宫颈癌患者联合放射治疗疗效的研究结果:其中153例(第1组)接受标准腔内伽马治疗,206例(第2组)——基于内置管和低活度放射性核素源连续插入原则的腔内伽马治疗,412例(第3组)——基于高活度源连续插入原则的腔内伽马治疗。患者在主要临床症状和肿瘤生物学特征方面具有可比性。结果发现第1组的放射反应和并发症发生率更高。在第1组中,I期宫颈癌患者的5年生存率为76.2±6.9%,II期患者为65.5±5.1%,III期肿瘤患者为39.2±9.2%。第2组的这些指标分别为95.7±2.9%、75.1±4%和58.5±7.7%,第3组分别为96.4±1.6%、85.9±2.8%和59.7±9.3%。作者证明了基于内置管和高活度源两阶段连续插入原则的腔内伽马治疗宫颈癌联合放射治疗方法的优势。